Trellis Bioscience
Redwood City, California, United States · Biotechnology, Health Care
Trellis Bioscience is a clinical-stage biotechnology company focused on developing native human monoclonal antibodies (mAbs) to treat intractable infectious diseases. The company is currently advancing its investigational treatment, calpurbatug (TRL1068), for chronic prosthetic joint infections. With substantial funding from various investors, Trellis aims to redefine the treatment for antibiotic-
Key facts
- Headquarters
- Redwood City, California, United States
- Employees
- 17
- Industries
- Biotechnology, Health Care
- Status
- Private
- Website
- trellisbio.com
- Company page
Recent activity at Trellis Bioscience
- : Trellis Bioscience raises $9 million in Series C funding to advance clinical development of Calpurbatug (TRL1068), targeting antibiotic-resistant infections. New and existing investors including AMR Action Fund and New Science Ventures participated.
- : Trellis Bioscience (date of first sale on the SEC Form D)
- : Trellis Bioscience (date of first sale on the SEC Form D)
- : Trellis Bioscience (date of first sale on the SEC Form D)
- : Trellis Bioscience (date of first sale on the SEC Form D)
Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.
Trellis Bioscience funding history
| Date | Round | Amount |
|---|---|---|
| Jul 2026 | Series C | $9.0M |
| Apr 2023 | Venture | $1.4M |
| Jun 2022 | Venture | $985K |
| Apr 2010 | Venture | $22.9M |
Leadership
- Stefan, President & CEO
- Geoffrey, Chief Business Officer
Verified email and direct lines for Trellis Bioscience’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.
Employee benefit plans
Trellis Bioscience files 3 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Companies similar to Trellis Bioscience
- Kardi Ai · Biotechnology, Health Care
- OpZira · Biotechnology, Health Care
- Raywatt · Biotechnology, Health Care
- EndoSound · Biotechnology, Health Care
- Advanced NanoTherapies · Biotechnology, Health Care
About Trellis Bioscience: questions and answers
What does Trellis Bioscience do?
Trellis Bioscience is a clinical-stage biotechnology company focused on developing native human monoclonal antibodies (mAbs) to treat intractable infectious diseases. The company is currently advancing its investigational treatment, calpurbatug (TRL1068), for chronic prosthetic joint infections. With substantial funding from various investors, Trellis aims to redefine the treatment for antibiotic-
Where is Trellis Bioscience headquartered?
Trellis Bioscience is headquartered in Redwood City, California, United States.
How many employees does Trellis Bioscience have?
Trellis Bioscience has about 17 employees.
Has Trellis Bioscience raised funding?
Yes. Fundz has recorded 4 funding events for Trellis Bioscience. The most recent, Series C of $9.0M, was in Jul 2026.
Who leads Trellis Bioscience?
Stefan is a President & CEO at Trellis Bioscience.
What is the latest news on Trellis Bioscience?
On Jul 16, 2026, Trellis Bioscience raises $9 million in Series C funding to advance clinical development of Calpurbatug (TRL1068), targeting antibiotic-resistant infections. New and existing investors including AMR Action Fund and New Science Ventures participated.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy